KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Deferred Revenue (2019 - 2021)

Xenon Pharmaceuticals (XENE) has disclosed Current Deferred Revenue for 6 consecutive years, with $2.2 million as the latest value for Q3 2021.

  • Quarterly Current Deferred Revenue fell 70.43% to $2.2 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Sep 2021, down 70.43% year-over-year, with the annual reading at $3.6 million for FY2020, 87.76% down from the prior year.
  • Current Deferred Revenue for Q3 2021 was $2.2 million at Xenon Pharmaceuticals, down from $3.0 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $29.7 million in Q4 2019, with the low at $2.2 million in Q3 2021.
  • Average Current Deferred Revenue over 3 years is $10.9 million, with a median of $5.5 million recorded in 2020.
  • The sharpest move saw Current Deferred Revenue plummeted 87.76% in 2020, then plummeted 70.43% in 2021.
  • Over 3 years, Current Deferred Revenue stood at $29.7 million in 2019, then tumbled by 87.76% to $3.6 million in 2020, then tumbled by 39.54% to $2.2 million in 2021.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $2.2 million, $3.0 million, and $3.6 million for Q3 2021, Q2 2021, and Q1 2021 respectively.